RA Drug May Help Treat Recalcitrant Eczema
Treatment with the janus kinase (JAK) inhibitor XELJANZ® (tofacitinib citrate) led to dramatic improvement in six patients with moderate to severe eczema who had previously failed conventional therapies.
Treatment with the janus kinase (JAK) inhibitor XELJANZ® (tofacitinib citrate) led to dramatic improvement in six patients with moderate to severe eczema who had previously failed conventional therapies.
The latest version features increased energy output, interchangeable spot sizes, and system upgrades aimed at enhancing multi-modal aesthetic treatments.